Skip to content

Ipamorelin Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

No FDA-approved dosing guidelines exist for ipamorelin. The following protocols are derived from clinical research and community reports:

  • Standard range: 100-200 mcg per administration, with injections performed once or twice daily
  • Most common protocol: 100-200 mcg administered once or twice daily, the bedtime dose is the most important, as it amplifies the natural nocturnal GH surge

Beginner Protocol

100 mcg once daily before bed, for 8-12 weeks. The bedtime dose capitalizes on the natural nocturnal GH surge and is the single most effective administration window.

Intermediate Protocol

100-200 mcg, twice daily (morning and before bed), for 8-12 weeks.

Advanced Protocol

200 mcg, two to three times daily, often combined with a GHRH analog such as CJC-1295, for 8-12 weeks.

Cycling Recommendations

Cycling is generally recommended, with 8-12 weeks on followed by 4-8 weeks off to prevent receptor desensitization and maintain pituitary sensitivity. The only published human trial used 7 days of continuous dosing; longer protocols are extrapolated from clinical rationale and community experience.

Timing Considerations

Administering ipamorelin on an empty stomach (at least 30 minutes before eating or 2 hours after) maximizes growth hormone release, as elevated blood glucose and insulin can blunt the GH response. The pre-bed dose capitalizes on the body's natural nocturnal GH surge.

Frequently Asked Questions

While some users employ extended protocols, cycling (12-16 weeks on, 4-8 weeks off) is generally recommended to maintain receptor sensitivity and pituitary responsiveness. Long-term safety data in humans is limited.

Yes, ipamorelin is used by both men and women at similar doses. Women may particularly benefit from its collagen-enhancing and anti-aging properties.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  2. Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561.
  3. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
  4. Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66.
  5. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231.
  6. Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
  7. World Anti-Doping Agency. Prohibited List.
  8. Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
  9. U.S. Food and Drug Administration.
  10. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008;149(9):601-611.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”